Alert: Major Price Decline (6/11/19)-Amsterdam Molecular Therapeutics (NASDAQ: QURE).


On 6/11/19, Amsterdam Molecular Therapeutics (NASDAQ: QURE) stock suffered a major decline of -12.0%, closing at $65.97. Moreover, this decline was accompanied by exceptionally high trading volume at 556% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 2.1% during the last week.


Current PriceTarget Research Rating

QURE is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.

Unicure has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Unicure has a very low Appreciation Score of 1 but a very high Power Rating of 89, triggering the Low Neutral Value Trend Rating.

Rating Review

In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.

About John Lafferty 47332 Articles
During his career, John has developed valuation and stock rating methodologies, managed institutional portfolios and mutual funds, and provided equity research to institutional investors on thousands of companies. He has been Director of Research at PTR since its inception in 2004.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.